share_log

WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

藥明康德股份有限公司(SHSE:603259)的股票正在上漲:強勁的財務數據是否在引導市場?
Simply Wall St ·  12/19 12:39

WuXi AppTec (SHSE:603259) has had a great run on the share market with its stock up by a significant 38% over the last three months. Since the market usually pay for a company's long-term fundamentals, we decided to study the company's key performance indicators to see if they could be influencing the market. In this article, we decided to focus on WuXi AppTec's ROE.

藥明康德(SHSE:603259)在股票市場上的表現非常出色,過去三個月其股票上漲了顯著的38%。由於市場通常關注公司的長期基本面,我們決定研究公司的關鍵績效因數,以看看它們是否可能影響市場。 在這篇文章中,我們決定重點關注藥明康德的ROE。

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

淨資產回報率或ROE是評估公司管理層如何有效利用公司資本的關鍵指標。簡單來說,它用於評估公司相對於其股本的盈利能力。

How Do You Calculate Return On Equity?

如何計算股本回報率?

ROE can be calculated by using the formula:

ROE可以通過以下公式計算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股東權益回報率 = 凈利潤(來自持續運營)÷ 股東權益

So, based on the above formula, the ROE for WuXi AppTec is:

因此,根據上述公式,藥明康德的ROE爲:

15% = CN¥8.2b ÷ CN¥56b (Based on the trailing twelve months to September 2024).

15% = CN¥82億 ÷ CN¥560億(基於截至2024年9月的過去十二個月)。

The 'return' is the amount earned after tax over the last twelve months. One way to conceptualize this is that for each CN¥1 of shareholders' capital it has, the company made CN¥0.15 in profit.

「回報」是過去十二個月稅後賺取的金額。一種概念化的方式是,對於每1元股東資本,公司賺取了0.15元的利潤。

Why Is ROE Important For Earnings Growth?

ROE爲什麼對凈利潤增長很重要?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.

我們已經確定,ROE作爲公司未來盈利的有效盈利生成指標。根據公司選擇再投資或 "保留 "其利潤的多少,我們能夠評估公司未來產生利潤的能力。一般而言,其他條件相同,具有高股本回報率和利潤保留的公司,其增長率高於沒有這些特徵的公司。

WuXi AppTec's Earnings Growth And 15% ROE

藥明康德的收益增長和15%的ROE

To begin with, WuXi AppTec seems to have a respectable ROE. Especially when compared to the industry average of 6.1% the company's ROE looks pretty impressive. Probably as a result of this, WuXi AppTec was able to see an impressive net income growth of 31% over the last five years. We reckon that there could also be other factors at play here. Such as - high earnings retention or an efficient management in place.

首先,藥明康德的ROE相當可觀。特別是與行業平均水平6.1%相比,該公司的ROE看起來相當令人印象深刻。可能由於這個原因,藥明康德在過去五年中實現了31%的凈利潤增長。我們認爲這裏可能還有其他因素在起作用,比如高收益留存或高效的管理。

As a next step, we compared WuXi AppTec's net income growth with the industry, and pleasingly, we found that the growth seen by the company is higher than the average industry growth of 17%.

作爲下一步,我們將藥明康德的凈利潤增長與行業進行了比較,令人高興的是,我們發現該公司的增長高於行業平均增長17%。

big
SHSE:603259 Past Earnings Growth December 19th 2024
SHSE:603259 過去的收益增長 2024年12月19日

Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. What is 603259 worth today? The intrinsic value infographic in our free research report helps visualize whether 603259 is currently mispriced by the market.

盈利增長是評估股票時需要考慮的重要指標。投資者應該嘗試判斷預期的盈利增長或下降,無論是哪種情況,是否已經被市場定價。這樣可以幫助他們判斷該股票的未來是光明還是黯淡。那麼603259今天值多少錢?我們免費研究報告中的內在價值信息圖有助於可視化603259是否被市場錯誤定價。

Is WuXi AppTec Efficiently Re-investing Its Profits?

藥明康德是否在有效地再投資其利潤?

WuXi AppTec's three-year median payout ratio is a pretty moderate 29%, meaning the company retains 71% of its income. By the looks of it, the dividend is well covered and WuXi AppTec is reinvesting its profits efficiently as evidenced by its exceptional growth which we discussed above.

藥明康德的三年中位數分紅比例爲29%,相對較爲適中,這意味着公司留存71%的收入。從表面上看,分紅覆蓋良好,藥明康德有效地再投資其利潤,這從我們上述討論的卓越增長中可以看出。

Moreover, WuXi AppTec is determined to keep sharing its profits with shareholders which we infer from its long history of five years of paying a dividend. Upon studying the latest analysts' consensus data, we found that the company is expected to keep paying out approximately 30% of its profits over the next three years. As a result, WuXi AppTec's ROE is not expected to change by much either, which we inferred from the analyst estimate of 16% for future ROE.

此外,藥明康德決心繼續與股東分享其利潤,這可以從其長達五年的分紅歷史中推斷得出。通過研究最新的分析師共識數據,我們發現預計公司將在未來三年內支付約30%的利潤。因此,藥明康德的ROE預計也不會有太大變化,這從分析師對未來ROE的16%的預測中可以推斷得出。

Summary

總結

On the whole, we feel that WuXi AppTec's performance has been quite good. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. That being so, a study of the latest analyst forecasts show that the company is expected to see a slowdown in its future earnings growth. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

總體而言,我們認爲藥明康德的表現相當不錯。特別是,看到公司對其業務進行了大量投資,並且有高回報率,這導致其收益有了顯著增長,這是很好的。儘管如此,最新的分析師預測研究表明,預計公司未來的收益增長將放緩。要了解更多關於該公司的最新分析師預測,請查看這張公司分析師預測的可視化圖。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論